Dent Neurologic Institute
Amherst, New York, 14226, United States
NCT Number: NCT02158585
This double-blinded study evaluates the frequency of vertigo attacks and the quality of life of patients diagnosed with Ménière's disease after being randomly assigned to take a placebo or lamotrigine.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 2
Amherst, New York, 14226, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Lamotrigine will be taken orally on a daily basis for the duration of 20 weeks, consisting of a six-week titration, 12-week study period, and two-week taper. Possible doses for patients are 25mg twice a day, 50mg twice a day, and 100 mg twice a day during titration; 150mg twice a day for the 12-week study period; 150mg once a day for Week 1 of the taper; and 75mg once a day for Week 2 of the taper. Each increase in dose will be maintained for two weeks before deciding to further increase or decrease based on tolerability. Patients who discontinue at any point of the study will have a two-week taper consisting of the current dose once a day for one week followed by half the dose once a day for another week.
Other names: Lamictal, 3,5-diamino-6-(2,3-dichlorophenyl)-as-triazine, U3H27498KS
The placebo will match the lamotrigine dosage, frequency and duration.
Other names: microcrystalline cellulose
Time frame: Duration of 12-week pre-treatment and 12-week study period (treatment)
Measured with a daily questionnaire
Time frame: Duration of 12-week pre-treatment and 12-week study period (treatment)
Measured with daily questionnaire
Time frame: Duration of Week 16 to 18
Measured with a daily questionnaire.
Time frame: Prior to randomization and at completion of 12-week study period
Measured using the average of 500, 1000, 2000, and 3000 Hz presentation level (dB)
Time frame: 12-week pre-treatment period; 6 week titration; 12-week study period (treatment)
Based of rating on Clinical Global Impression of Change (CGI) score of blinded physician
Time frame: Baseline (Week 1) and end of study (Week 18)
Dizziness Handicap Inventory (DHI). Minimum score=0. Maximum score=100. Higher scores mean a worse outcome.
Dent Neuroscience Research Center
Other
Lamotrigine for Ménière's Disease: a Double-blind, Placebo-controlled Pilot Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06859788
Dizziness, Ear Diseases
Los Angeles, California, United States
View Trial DetailsNCT02603081
Ear Diseases, Endolymphatic Hydrops
Los Angeles, California, United States
View Trial DetailsNCT03325790
Behavior, Communication
Fresno, California, United States
View Trial DetailsNCT02612337
Ear Diseases, Endolymphatic Hydrops
San Diego, California, United States
View Trial Details